Stockreport

Seattle Genetics Announces U.S. FDA Approval of TUKYSA™ (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

Seagen Inc.  (SGEN) 
Last seagen inc. earnings: 4/30 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.seattlegenetics.com
PDF -Approved for Patients with HER2-Positive Metastatic Breast Cancer Who Have Received One or More Prior Anti-HER2 Therapies in the Metastatic Setting--First HER-2 Tyrosin [Read more]